Maraviroc - A CCR5 Antagonist for the Treatment of HIV-1 Infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. The Association betweenViruses · 2023
   Pooled it
2. HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis.AIDS research and therapy · 2020
   Pooled it
3. Decoding GPCR signaling reprogramming in cancer: molecular mechanisms and therapeutic implications.Molecular medicine (Cambridge, Mass.) · 2026
   Review
4. D-dimer drives immune dysregulation in COVID-19 via chemokine modulation and inflammatory signaling.Virus research · 2025
   Article
5. Exploiting allosteric modulation: a new frontier for precision medicine.Molecular biology reports · 2025
   Review
6. Turning "trashed" genomic loci into treasurable sites for integrating chimeric antigen receptors in T and NK cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
   Review
7. Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.Nature reviews. Drug discovery · 2025
   Review
8. 30 years of HIV therapy: Current and future antiviral drug targets.Virology · 2025
   Review
9. Molecular Role of HIV-1 Human Receptors (CCL5-CCR5 Axis) in neuroAIDS: A Systematic Review.Microorganisms · 2024
   Review
10. Structural basis of dimerization of chemokine receptors CCR5 and CXCR4.Nature communications · 2023
    Article
11. Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies.Biomarker research · 2023
    Review
12. The Influence BetweenAIDS research and human retroviruses · 2023
    Review
13. Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.PLoS pathogens · 2022
    Review
14. Filling the Gaps in Antagonist CCR5 Binding, a Retrospective and Perspective Analysis.Frontiers in immunology · 2022
    Article
15. A new microtubule-stabilizing agent shows potent antiviral effects against African swine fever virus with no cytotoxicity.Emerging microbes & infections · 2021
    Article
16. Novel Antiretroviral Therapeutic Strategies for HIV.Molecules (Basel, Switzerland) · 2021
    Review
17. Hepatitis B virus-host interactions and novel targets for viral cure.Current opinion in virology · 2021
    Review
18. An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs: General Principles and Current Status.Infection & chemotherapy · 2021
    Review
19. Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.Virus research · 2020
    Review
20. A degradatory fate for CCR4 suggests a primary role in Th2 inflammation.Journal of leukocyte biology · 2020
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as